The Evolution of Next Generation Generics
Nextgen Pharmaceuticals, LLC, based in New York, was established in July 2015 and is an emerging pharmaceutical company. Together with its strategic partners, Nextgen is collaboratively developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories.
With a primary focus on Oncology and Immuno-suppressant medication, Nextgen currently has more than 15 products in pipeline subject to FDA approval. In addition, Nextgen continues to pursue licensing opportunities to compliment its expanding portfolio.